Improving the Clinical and Economic Burden of Ankylosing Spondylitis: Targeting IL17/IL-23 Pathways for Optimized Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of AS, including
how to translate the most recent data into clinical and administrative practice.

These are archives of live webinars held between February 21 to February 28, 2020.
If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

Each session has its own specific valid dates

This series is supported by educational grants from
Lilly and Novartis Pharmaceuticals Corporation
 

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Ankylosing spondylitis (AS) is an immune-mediated chronic inflammatory disease that typically affects the sacroiliac (SI) joints. Patients with AS suffer from debilitating pain and joint fusion that severely limits their mobility and functional capacity. It is estimated that AS affects approximately 1.6 million people in the US. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and costly. Fortunately for patients with this disease, recent advances in pathogenesis have led to an increased understanding of the disease, which has subsequently led to the development of novel targeted agents shown to slow its progression, including options targeting IL-17/IL-23 pathways.

This webinar series on integrating IL-17 and IL-23 therapies into the treatment paradigm will provide attendees with updated education on these novel treatment options, emerging value equations, the limitations of established treatment options, and recent clinical data on these new agents to optimize the management of patients with AS.


Comparative Effectiveness and Payer-Provider Coordination in Ankylosing Spondylitis: Managed Care Insights on IL-17/23 Inhibitors

  1. Assess the burden of ankylosing spondylitis and the role of managed care professionals in the management of ankylosing spondylitis
  2. Analyze efficacy and safety profiles of IL-17 and IL-23 inhibitors for ankylosing spondylitis
  3. Discuss the managed care considerations of IL-17 and IL-23 inhibitors by exploring where these agents fit in the current ankylosing spondylitis management paradigm
  4. Identify co-productive payer-provider strategies to ensure appropriate and timely access to IL-17 and IL-23 inhibitors for patients with ankylosing spondylitis
          Physician, Nursing and CMCN credits valid to April 1, 2022

A Closer Look at IL-17 and IL-23 Inhibitors in the Treatment of Ankylosing Spondylitis: Individualizing Therapy for Improved Clinical and Economic Outcomes

  1. Recognize current challenges in classification and diagnosis of axial spondyloarthritis and ankylosing spondylitis (axSpA/AS)
  2. Discuss unmet needs in the early recognition, diagnosis and management of axSpA/AS (including co-morbidities)
  3. Explore the role of the IL-23/IL-17A axis in the pathogenesis of axSpA/AS
  4. Review the data on efficacy and safety of IL-17A and IL-23 inhibitors in axSpA/AS
  5. Evaluate tools for the assessment of disease activity and monitoring of treatment responses in axSpA/AS
  6. Discuss treat-to-target and personalized medicine approaches in axSpA/AS
          Physician, Nursing and CMCN credits valid to April 1, 2022

Improving Patient Adherence and Quality of Life in Ankylosing Spondylitis: Strategies for Managing Treatment Related Adverse Events Associated with IL-17 Inhibitors

  1. Explore challenges to patient adherence and quality of life in ankylosing spondylitis
  2. Incorporate classification criteria and diagnostic tests into clinical practice to support early detection of ankylosing spondylitis
  3. Analyze strategies to monitor and manage adverse events associated with IL-17 inhibitors in ankylosing spondylitis management in order to improve patient adherence
  4. Review recent clinical data around the safety of IL-17 inhibitors and their effect on patient quality of life
          Physician, Nursing and CMCN credits valid to April 1, 2022